



Amedisys Second Quarter 2022 Earnings Call  
Supplemental Slides  
July 28<sup>th</sup>, 2022

# Forward-looking statements

This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those described in this presentation. You should not rely on forward-looking statements as a prediction of future events.

Additional information regarding factors that could cause actual results to differ materially from those discussed in any forward-looking statements are described in reports and registration statements we file with the SEC, including our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, copies of which are available on the Amedisys internet website <http://www.amedisys.com> or by contacting the Amedisys Investor Relations department at (225) 292-2031.

We disclaim any obligation to update any forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based except as required by law.

**[www.amedisys.com](http://www.amedisys.com)**

**NASDAQ: AMED**

We encourage everyone to visit the Investors Section of our website at [www.amedisys.com](http://www.amedisys.com), where we have posted additional important information such as press releases, profiles concerning our business, clinical operations and control processes and SEC filings.

# Our Key Areas of Focus

Strategic areas of focus and progress made during Q2'22

1



## Organic Growth

- **Home Health\***: Total same store admissions flat
- **Hospice**: Total same store admissions +6%, ADC flat; +2.5% sequentially
- **Personal Care**: PC Network drove ~\$406K in revenue to Home Health and Hospice via care coordination

2



## Recruiting / Retention

- Targeting industry leading employee retention amongst all employee categories
- Q2'22 Voluntary Turnover 20.9%

3



## Clinical Initiatives

- Quality: Amedisys Apr'22 release STARS score of 4.38 (SHP: 4.5 STARS)
- 100% of care centers at 4+ Stars based on Oct'22 preview
- 52 Amedisys care centers rated at 5 Stars in the Oct'22 preview
- Hospice quality – outperforming industry average in all hospice item set (HIS) categories

4



## Capacity and Productivity

- Focusing on optimizing RN / LPN & PT / PTA staffing ratios.
  - Current LPN Ratio: 47.7% (vs. 47.5% in 2Q'21)
  - Current PTA Ratio: 53.4% (vs. 52.9% in 2Q'21)

5



## M&A

- Acquired Evolution Health on 4/1/22 expanding our footprint in TX, OK and OH (15 care centers)
- Acquired 2 care centers from Assisted Care Home Health in North Carolina on 4/1/22
- Entered into 2 new High Acuity Care joint venture partnerships during Q2

6



## Regulatory

### 2022 Reimbursement

- Final Home Health industry rule net +3.2% increase
- Final Hospice industry rule net +2.0% increase (effective 10/1/21)

### 2023 Reimbursement

- Proposed FY'23 Hospice industry rule net +2.7% increase (effective 10/1/22)
- Proposed FY'23 Home Health industry rule net -4.2% decrease (effective 1/1/23)
- The Preserving Access to Home Health Act of 2022 introduced to protect Home Health providers and patients from the extreme cuts outlined in the proposed rule

\*Note: Home Health same store volume is defined as admissions plus recertifications



# Highlights and Summary Financial Results (Adjusted): 2Q 2022<sup>(1)</sup>

Home Health total same store admissions flat; Hospice same store admissions +6%; EBITDA margin decline driven by the addition of Contessa, labor costs and the return of sequestration



### Amedisys Consolidated

- Revenue Growth: +2%
- EBITDA: \$74M (-11%, ex. Contessa -2%)
- EBITDA Margin: 13.1% (ex. Contessa: 14.6%)
- EPS: \$1.47 (-13%)

Adjusted Financial Results		
\$ in Millions, except EPS	2Q21	2Q22
Home Health	\$ 349.3	\$ 348.5
Hospice	191.4	198.4
Personal Care	17.0	14.9
High Acuity Care	-	4.4
<b>Total Revenue</b>	<b>\$ 557.6</b>	<b>\$ 566.3</b>
Gross Margin %	45.4%	44.9%
<b>Adjusted EBITDA</b>	<b>\$ 83.8</b>	<b>\$ 74.4</b>
	<b>15.0%</b>	<b>13.1%</b>
<b>Adjusted EPS</b>	<b>\$ 1.69</b>	<b>\$ 1.47</b>
<b>Free cash flow<sup>(4)</sup></b>	<b>\$ 64.3</b>	<b>\$ 52.7</b>

### Balance Sheet & Cash Flow

- Net debt: \$410.2M
- Net Leverage ratio: 1.5x
- Revolver availability: \$507.3M
- CFFO: \$57.4M
- Free cash flow<sup>(4)</sup>: \$52.7M
- DSO: 46.8 (vs. Q4'21 of 43.2 and up 0.5 days since Q1)

### Home Health

Same Store<sup>(2)(3)</sup>:

- Total Admissions: Flat
- Total Volume: -2%

Other Statistics:

- Revenue per Episode<sup>(5)</sup>: \$3,048 (+2.1%)
- Visiting Clinician Cost per Visit: \$95.49 (+6.0%)
- Medicare VPE decreased 1.0 (-7.0%)

### Hospice

Same Store Volume<sup>(3)</sup>:

- Admissions: +6%
- ADC: Flat

Other Statistics:

- Revenue per Day: \$164.55 (+3.7%)
- Cost per day: \$88.21 (+3.4%)

### Personal Care

Growth Metrics:

- Billable hours/quarter: -22%
- Clients served: -17%

Other Statistics:

- Revenue per hour: +13%
- Cost per hour: +13%

### High Acuity Care

Growth Metrics:

- Total Admissions: 345
- Number of admitting JV's: 9

Other Statistics:


- Patient Satisfaction: 89%

1. The financial results for the three-month periods ended June 30, 2021 and June 30, 2022 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.
2. Same Store volume – Includes admissions and recertifications.
3. Same Store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center.
4. Free cash flow is defined as cash flow from operations less routine capital expenditures and required debt repayments.
5. Medicare sequestration suspended May 1, 2020; reinstated at 1% effective April 1, 2022.




# Our Revenue Sources: 2Q'22


## Amedisys Consolidated Revenue



## Home Health Revenue



## Hospice Revenue



- **Home Health:** 353 care centers; 34 states & D.C.
- **Hospice:** 174 care centers; 34 states
- **Personal Care:** 14 care centers; 3 states
- **High Acuity Care:** 9 admitting joint ventures; 7 states; 25 referring hospitals
- **Total AMED:** 550 care centers; 38 states and D.C.

- **Medicare FFS:** Reimbursed over a 30-day period of care
- **Private Episodic:** MA and Commercial plans who reimburse us over a 30-day period of care, majority of which range from 95% - 100% of Medicare rates
- **Per Visit:** Managed care, Medicaid and private payors reimbursing us per visit performed

- Hospice Per Day Reimbursement:**
- **Routine Care:** Patient at home with symptoms controlled ~97% of the Hospice care AMED provides, in line with overall hospice industry provision of care
  - **Continuous Care:** Patient at home with uncontrolled symptoms
  - **Inpatient Care:** Patient in facility with uncontrolled symptoms
  - **Respite Care:** Patient at facility with symptoms controlled



# Home Health and Hospice Segment (Adjusted) – 2Q 2022<sup>(1)</sup>



HOME HEALTH		
\$ in Millions	2Q21	2Q22
Medicare	\$ 234.8	\$ 230.3
Non-Medicare	114.5	118.2
<b>Home Health Revenue</b>	<b>\$349.3</b>	<b>\$348.5</b>
Gross Margin %	46.1%	45.6%
<b>Pre-Corporate EBITDA <sup>(2)</sup></b>	<b>\$80.1</b>	<b>\$71.5</b>
	22.9%	20.5%

HOSPICE		
\$ in Millions	2Q21	2Q22
Medicare	\$ 180.4	\$ 187.5
Non-Medicare	11.0	10.9
<b>Hospice Revenue</b>	<b>\$191.4</b>	<b>\$198.4</b>
Gross Margin %	46.2%	46.4%
<b>Pre-Corporate EBITDA <sup>(2)</sup></b>	<b>\$40.6</b>	<b>\$41.8</b>
	21.2%	21.1%

Operating Statistics		
<u>Same Store Growth <sup>(3)(4)</sup></u>		
Total admissions	20%	0%
Total volume	12%	-2%
Medicare revenue per episode <sup>(5)</sup>	\$2,986	\$3,048
Medicare recert rate	34.4%	33.6%
Total cost per visit	\$99.39	\$106.16

Operating Statistics		
Admit growth - same store <sup>(3)(4)</sup>	2%	6%
ADC growth - same store <sup>(3)(4)</sup>	-3%	0%
ADC	13,254	13,249
Avg. discharge length of stay	97	87
Revenue per day (net)	\$158.67	\$164.55
Cost per day	\$85.33	\$88.21



## Home Health Highlights

- Revenue per Episode up 2.1% (primarily due to +3.2% rate increase effective 1/1/2022 partially offset by the reinstatement of sequestration at 1%)
- Y/Y Total CPV up \$6.77 (+6.8%, primarily due to planned wage increases, wage inflation, sign-on bonuses, higher new hire pay, an increase in salaried employees and visit mix)
- Visits per episode decreased 1.0 (Medicare)
- Cost per episode down 1.8% (Medicare)



## Hospice Highlights

- Net revenue per day +3.7% (primarily due to +2.0% Hospice rate update effective 10/1/2021 and lower revenue adjustments partially offset by the reinstatement of sequestration at 1%)
- Cost per day up \$2.88 (+3.4% primarily due to planned wage increases, wage inflation and sign-on bonuses)
- ADC +2.5% sequentially

1. The financial results for the three-month periods ended June 30, 2021 and June 30, 2022 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.
2. Pre-Corporate EBITDA does not include any corporate G&A expenses.
3. Same Store information represents the percent change in volume, admissions or ADC for the period as a percent of the volume, admissions or ADC of the prior period.
4. Same Store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center.
5. Average Medicare revenue per completed episode reflects the suspension of sequestration for the period May 1, 2020 – March 31, 2022 and the reinstatement of sequestration at 1% for the period April 1, 2022 – June 30, 2022.




# General & Administrative Expenses – Adjusted <sup>(1,2)</sup>

Impacted by acquisitions, raises and the addition of resources to support growth

\$ in Millions	2Q21	3Q21	4Q21	1Q22	2Q22
<b>Home Health Segment - Total</b>	<b>81.3</b>	<b>82.4</b>	<b>84.7</b>	<b>83.2</b>	<b>87.8</b>
% of HH Revenue	23.3%	24.3%	25.1%	24.8%	25.2%
<b>Hospice Segment - Total</b>	<b>48.4</b>	<b>49.5</b>	<b>54.0</b>	<b>51.3</b>	<b>50.8</b>
% of HSP Revenue	25.3%	25.1%	26.4%	26.6%	25.6%
<b>Personal Care Segment - Total</b>	<b>3.1</b>	<b>2.6</b>	<b>2.4</b>	<b>2.2</b>	<b>2.3</b>
% of PC Revenue	18.1%	16.5%	15.7%	15.8%	15.2%
<b>High Acuity Care Segment - Total</b>	<b>-</b>	<b>3.8</b>	<b>6.2</b>	<b>7.1</b>	<b>8.8</b>
% of HAC Revenue	-%	255.2%	305.7%	256.9%	199.8%
<b>Total Corporate Expenses</b>	<b>38.1</b>	<b>37.7</b>	<b>36.1</b>	<b>35.6</b>	<b>32.7</b>
% of Total Revenue	6.8%	6.8%	6.5%	6.5%	5.8%
<b>Total</b>	<b>170.9</b>	<b>176.0</b>	<b>183.4</b>	<b>179.4</b>	<b>182.4</b>
% of Total Revenue	30.7%	31.8%	32.8%	32.9%	32.2%

	2Q21	3Q21	4Q21	1Q22	2Q22
Salary and Benefits	22.0	22.1	21.7	23.8	23.3
Other	11.6	12.8	10.4	10.2	6.7
Corp. G&A Subtotal	33.6	34.9	32.1	34.0	30.1
Non-cash comp	4.5	2.8	4.0	1.6	2.6
<b>Adjusted Corporate G&amp;A</b>	<b>38.1</b>	<b>37.7</b>	<b>36.1</b>	<b>35.6</b>	<b>32.7</b>



## Notes:

- **Year over year total G&A as a percentage of revenue increased 150 basis points (\$12 million); \$1 million decrease excluding Contessa (\$9 million) and home health acquisitions (\$4 million) (G&A as a % of revenue excluding Contessa and home health acquisitions = 30.9%)**
  - Decrease due to a favorable legal settlement and higher gains on the sale of fleet vehicles partially offset by the addition of resources to support growth, planned wage increases, higher travel and training spend and increased information technology fees.
- **Total G&A decreased \$1 million sequentially excluding our home health acquisitions**

1. The financial results for the three-month periods ended June 30, 2021, September 30, 2021, December 31, 2021, March 31, 2022 and June 30, 2022 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.

2. Adjusted G&A expenses do not include depreciation and amortization.


# Operational Excellence: Home Health Cost Per Visit (CPV)-Adjusted



YOY Total CPV impacted by labor cost pressures and lower visits

Components	2Q'21	1Q'22	2Q'22	YoY Variance	Detail	Initiatives
Salaries	\$65.02	\$70.30	\$69.81	\$4.79	YoY increase due to visit mix, planned wage increases, wage inflation, sign-on bonuses, new hire pay and an increase in salaried employees	Staffing mix optimization, productivity and scheduling improvement initiatives in place to help overcome salary increases
Contractors	\$5.10	\$5.61	\$4.68	\$(0.42)	YoY and Sequential variances due to lower utilization of contract staff. YoY utilization decrease is partially offset by an increase in contractor rates	Focused efforts on filling positions with full-time clinicians (utilization down from 4.4% to 3.5%)
Benefits	\$13.18	\$12.42	\$13.50	\$0.32	YoY increase due to higher payroll taxes on the salary increases/bonuses described above  Sequential increase due to health insurance and the seasonality of claims	Focus on cost containment and spend optimization with specific focus on high-cost claims
Transportation & Supplies	\$6.78	\$7.31	\$7.50	\$0.72	YoY variance due to higher fleet fuel costs and rate increases for freight and certain supplies	
<b>*Visiting Clinician CPV</b>	<b>\$90.08</b>	<b>\$95.64</b>	<b>\$95.49</b>	<b>\$5.41</b>		
Clinical Managers	\$9.31	\$10.62	\$10.67	\$1.36	Fixed cost associated with non-visiting clinicians  YoY increase driven by additional staff, planned wage increases and impact of fixed costs on lower visit volumes	Unit cost reduced as volume increases
Total CPV	\$99.39	\$106.26	\$106.16	\$6.77		

\*Note: Direct comparison with industry competitors CPV calculation








# Driving Top Line Growth

Home Health total volume and Personal Care billable hours lagging due to prolonged COVID-19 impacts (lower utilization and staffing challenges). Hospice volume metrics continue to improve as both admissions and average daily census were the highest for the periods presented below.



# Industry Leading Quality Scores




## Quality of Patient Care (QPC)

Metric	JAN 22 Release	APR 22 Release	Jul 22 Preview	Oct 22 Preview
Quality of Patient Care	4.33	4.38	4.46	<b>4.49</b>
Entities at 4+ Stars	92%	97%	99%	100%


## Patient Satisfaction (PS)

Metric	OCT 20 Release	JAN 22 Release	APR 22 Release	Jul 22 Preview
Patient Satisfaction Star	4.28	3.61	3.73	<b>3.92</b>
Performance Over Industry	+7%	+3%	+3%	+5%

### QPC Industry Performance





### PS Industry Performance



- Amedisys maintains a 4-Star average in the Oct 2022 HHC Preview with **100% of our providers (representing 100% of care centers) at 4+ Stars** and **82% of our providers (representing 86% of care centers) at 4.5+ Stars**.
- 29 Amedisys providers **(representing 52 care centers) rated at 5 Stars**.

Notes: (1) CMS did not provide QPC Star and HH-CAHPS performance releases in 2021 due to COVID-19 PHE. (2) Oct 2022 QPC Star Preview performance period = CY 2021 (Jul 2020 - Jun 2021 for ACH). (3) Jul 2022 HH-CAHPS Preview performance period = CY 2021 (4) QPC Star and HH-CAHPS Results for Amedisys Legacy providers only.

# Hospice Quality: Amedisys Hospice Continues to Move Towards Best-in-Class



**Notes:** Included in the above analysis are active care centers. HIS data includes all active care centers. CAHPS excludes Asana, AseraCare, and CCH acquisitions as they were acquired after the start of the reporting window.

# Debt and Liquidity Metrics

Net leverage ~1.5x

Outstanding Debt	As of: 6/30/22
Outstanding Revolver	15.0
Outstanding Term Loan	441.6
Promissory Notes	0.2
Finance Leases	2.2
<b>Total Debt Outstanding</b>	<b>459.0</b>
Less: Deferred Debt Issuance Costs	(4.1)
<b>Total Debt - Balance Sheet</b>	<b>454.9</b>
Total Debt Outstanding	459.0
Less Cash	(48.8)
<b>Net Debt <sup>(1)</sup></b>	<b>410.2</b>
Leverage Ratio (net) <sup>(2)</sup>	<b>1.5</b>
Credit Facility	As of: 6/30/22
Term Loan	450.0
Revolver Size	550.0
Borrowing Capacity	1,000.0
Revolver Size	550.0
Outstanding Revolver	(15.0)
Letters of Credit	(27.7)
<b>Available Revolver</b>	<b>507.3</b>
Plus Cash	48.8
<b>Total Liquidity <sup>(3)</sup></b>	<b>556.1</b>

1. Net debt defined as total debt outstanding (\$459.0M) less cash (\$48.8M).

2. Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA (\$277.8M).

3. Liquidity defined as the sum of cash balance and available revolving line of credit.

## Cash Flow Statement Highlights <sup>(1)</sup>

Q2 cash flow statement reflects two home health acquisitions and the buyback of 150,000 shares during the quarter. The second half of the COVID-19 relief payroll tax deferral (\$27M) is due in December 2022.

\$ in Millions	2Q21	3Q21	4Q21	1Q22	2Q22
GAAP Net Income	80.6	45.2	34.0	31.7	29.0
Changes in working capital	(9.1)	(7.0)	(27.1)	(5.4)	13.6
Depreciation and amortization	6.7	7.5	9.1	8.0	6.2
Non-cash compensation	6.2	4.4	5.9	7.3	5.1
Deferred income taxes	15.3	12.0	9.9	3.2	2.8
Other	(31.7)	(0.3)	(26.6)	3.8	0.7
<b>Cash flow from operations</b>	<b>68.0</b>	<b>61.8</b>	<b>5.2</b>	<b>48.6</b>	<b>57.4</b>
Capital expenditures - routine	(1.0)	(2.2)	(0.7)	(0.9)	(1.5)
Required debt repayments	(2.7)	(0.5)	(3.3)	(3.8)	(3.2)
<b>Free cash flow</b>	<b>64.3</b>	<b>59.1</b>	<b>1.2</b>	<b>43.9</b>	<b>52.7</b>
<b>Capital Deployment</b>					
Acquisitions	(2.5)	(262.4)	(5.1)	-	(73.3)
Share Repurchases	(1.2)	(10.8)	(15.0)	-	(17.4)
<b>Total</b>	<b>(3.7)</b>	<b>(273.2)</b>	<b>(20.1)</b>	<b>-</b>	<b>(90.7)</b>

1. Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments.

# Income Statement Adjustments <sup>(1)</sup>

Q2-22 Contingency accrual relates to a ZPIC audit stemming from a 2015 acquisition.

\$000s	Income Statement Line Item	2Q21	3Q21	4Q21	1Q22	2Q22
<b>Revenue</b>						
Contingency accrual	Net Service Revenue	\$ (6,541)	\$ -	\$ -	\$ -	\$ 8,374
<b>Other Operating Income</b>						
CARES Act funds	Other Operating Income	(4,603)	4	-	-	-
<b>Cost of Service</b>						
Severance - reduction in staffing levels	Cost of Service, Excluding Depreciation & Amortization	-	-	-	-	195
COVID-19 costs	Cost of Service, Excluding Depreciation & Amortization	4,464	3,513	4,323	3,733	1,803
Integration costs	Cost of Service, Excluding Depreciation & Amortization	-	-	-	-	1,401
Fuel supplement	Cost of Service, Excluding Depreciation & Amortization	-	-	-	337	1,016
<b>G&amp;A</b>						
Acquisition and integration costs	G&A, Salaries and benefits	510	1,071	419	316	1,674
Severance - reduction in staffing levels	G&A, Salaries and benefits	-	-	-	-	810
COVID-19 costs	G&A, Salaries and benefits	9	60	9	24	12
Executive Board of Directors transition award	G&A, Salaries and benefits	-	-	-	3,500	-
Acquisition and integration costs	G&A, Other	1,783	1,686	891	1,062	3,649
Legal fees - non-routine	G&A, Other	-	-	-	51	190
COVID-19 costs	G&A, Other	151	139	131	129	72
Planned closures - lease terminations	G&A, Other	-	-	-	-	59
Pre-acquisition legal settlement	G&A, Other	1,825	-	-	-	-
Legal settlement	G&A, Other	-	-	-	-	(1,058)
<b>Other Items</b>						
Interest component of certain items	Interest Expense	469	451	451	-	4,652
Other (income) expense, net (2)	Total Other (Expense) Income, Net	(31,077)	(66)	188	2,298	760
<b>Total</b>		<b>\$ (33,010)</b>	<b>\$ 6,858</b>	<b>\$ 6,412</b>	<b>\$ 11,450</b>	<b>\$ 23,609</b>
<b>EPS Impact</b>						
		<b>\$ (0.74)</b>	<b>\$ 0.17</b>	<b>\$ 0.15</b>	<b>\$ 0.26</b>	<b>\$ 0.56</b>
<b>EBITDA Impact</b>						
		<b>\$ (33,479)</b>	<b>\$ 6,407</b>	<b>\$ 5,961</b>	<b>\$ 11,450</b>	<b>\$ 18,957</b>

1. The financial results for the three-month periods ended June 30, 2021, September 30, 2021, December 31, 2021, March 31, 2022 and June 30, 2022 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period.

2. Other (income) expense, net includes ~\$31.1 million gain on Medalogix equity method investment for the three-month period ended June 30, 2021.



## 2022 Guidance

# Amedisys 2022 Updated Guidance

Revenue (updated); EBITDA and EPS (maintained)

<i>(\$M except for EPS)</i>	Original Guidance	Updated Guidance
Adjusted Revenue	<b>\$2,330 - \$2,365</b>	<b>\$2,290 - \$2,310</b>
Adjusted EBITDA	<b>\$275 - \$285</b>	<b>\$275 - \$285</b>
Adjusted EPS	<b>\$5.23 - \$5.45</b>	<b>\$5.23 - \$5.45</b>

## Guidance Disclaimer

COVID-19 has impacted the operating metrics typically used to forecast both growth and cost assumptions for both core Amedisys and Contessa. We are basing our guidance on our current operating environment. COVID-19 continues to evolve in both the disease itself as well as disruptions to the healthcare systems and the economy. Any future regulations or government interventions, spike in clinicians and BD staff on quarantine, staffing shortages due to current and proposed federal, state and local vaccine mandates, reduction in elective procedures, change in patient behavior and further decline in senior living occupancy could impact our ability to achieve this guidance.

## Environmental, Social, Governance (E.S.G.) Considerations

# Environmental, Social, Governance (E.S.G.) Considerations

Sustainable, high-quality, patient focused, home-based care model



Environmental	Social	Governance
<ul style="list-style-type: none"> <li>Amedisys is dedicated to the sustainability of our business and the communities in which we serve</li> <li>Environmental health has a strong correlation with physical health</li> <li>A greener fleet – newer vehicles, in circulation for a shorter time, optimize fuel usage. Sophisticated scheduling practices reduce our clinicians’ driving time and fuel usage helping to minimize our carbon footprint</li> <li>Virtual care centers, along with flexible working schedules and locations, have created fewer emissions</li> </ul>	<ul style="list-style-type: none"> <li>Amedisys strives to create an organizational culture and climate in which every individual is valued, all team members have a sense of belonging with one another and to the organization and feel empowered to do their best work</li> <li>Provider of Home Health and Hospice services to frail, elderly patients in their most preferred care location – their homes</li> <li>Highest quality Home Health company as measured by Quality of Patient Care Star scores (4.46 Stars)</li> <li>The Amedisys Foundation was formed to provide support to our patients and employees. The Amedisys Foundation has two funds: the Patients’ Special Needs Fund and the Amedisys Employees 1st Fund. The Patients’ Special Needs Fund provides financial assistance to our home health, hospice and personal care patients during a difficult time</li> </ul>	<ul style="list-style-type: none"> <li>Amedisys has a culture of compliance starting with oversight from the Board of Directors and cascading down to the care center level</li> <li>Our Board of Directors operates several sub-committees including:                             <ul style="list-style-type: none"> <li>Quality of Care Committee</li> <li>Compliance &amp; Ethics Committee</li> <li>Audit Committee</li> <li>Compensation Committee</li> <li>Nominating &amp; Corporate Governance Committee</li> </ul> </li> <li>Nominating and Corporate Governance Committee oversees our strategy on corporate social responsibility, including evaluating the impact of Company practices on communities and individuals, and develops and recommends to our Board of Directors for approval matters relating to the Company’s corporate social responsibility and ESG considerations</li> </ul>